#GLP-1 class

Coverage of the GLP-1 receptor agonist family and its successors.

A six-trial meta-analysis linked GLP-1-based therapies to fewer apnea events, but high heterogeneity limits the pooled estimate.

REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.

What Ozempic and Wegovy labels say about diarrhea, why a symptom report cannot prove causation, and when official guidance calls for assessment.

A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.

A guide to Wegovy's official adverse-reaction and warning language, and why a forum report cannot diagnose what caused one person's symptoms.

A 2026 narrative review maps aesthetic-surgery concerns after GLP-1-related weight loss but reports no new trial or proven drug-specific effect.

A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.

Rat and minipig HFpEF models showed cardiac and liver changes without substantial weight loss, but they cannot establish human efficacy.

A MENA expert panel interprets semaglutide and resmetirom evidence for MASH, with access and regional data gaps central to adoption.

Two 2026 letters discuss missed oral semaglutide doses, but inaccessible text limits what can be verified beyond the current product label.

An engineered GLP-1/GIP molecule led its mouse-study comparisons, but the preclinical result cannot predict human weight loss or safety.

SURPASS-EARLY found larger two-year HbA1c and weight reductions with tirzepatide than flexible conventional care in early type 2 diabetes.